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Introduction
Heterozygous germline mutations in NLRP3 are a
known cause of Cryopyrin associated periodic syndrome
(CAPS). However, in a considerable number of these
patients mutations cannot be detected by conventional
genetic analyses. Somatic mosaicism has been detected
in several mutation-negative patients, and is suggested
to be a major cause of CAPS in these patients.
Objectives
Using next-generation sequencing (NGS), we aimed to
investigate whether mosaicism for NLRP3 mutations
was present in mutation-negative CAPS patients.
Methods
Six well-defined mutation-negative CAPS patients were
included. In addition two CAPS patients that were identi-
fied before as mosaics, by a subcloning and Sanger
sequencing method, were included for validation purposes.
In short, barcoded whole genome fragment libraries were
generated for each patient, enriched for the coding regions
of 300 inflammation related genes using a custom Agilent
1M microarray and subsequently sequenced on the
SOLiD5500XL platform. Because almost all NLRP3 muta-
tions are located in exon 3 of NLRP3, this exon was
analyzed using an in house bioinformatic pipeline, CAR-
TAGENIA BENCH lab NGS and IGV2.2 software.
Results
In all patients all NLRP3 exons were 100% covered, with
an average coverage of 460x. The two patients that were
identified before as being 6.3% mosaic for the E567K
and G755R mutation demonstrated mosaicism for these
mutations of subsequently approximately 8% and 10%.
This indicated the method was valid to study mosaicism.
We could not detect mosaicism for known pathogenic
mutations in exon 3 in the six patients. However, in one
patient 9% mosaicism for an E567G variant was
detected. Although this variant has not been described
as heterozygous mutation in CAPS patients, mosaicism
for this variant has been described before in a mutation-
negative CAPS patient. The clinical relevance of this
variant, however, remains uncertain.
Conclusion
We demonstrated that our NGS method is a reliable,
accurate method to identify mosaic percentages of at least
8-10%. In contrast to the earlier reported finding that in
70 percent of mutation-negative CAPS patients mosaicism
for NLRP3 mutations can be demonstrated, we could not
find evidence for mosaicism in exon 3 of NLRP3 in five of
our six patients. Although very low mosaic percentages or
mosaic mutations in other exons cannot be excluded, this
suggests that next to germline and mosaic NLRP3 muta-
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